Major Interest in Shares

RNS Number : 9738U

Alliance Pharma PLC

09 December 2013

 



9 December 2013

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Major Interest in Shares

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that MVM Fund III LP and MVM Fund III (no 2) LP, acting by their fund manager MVM Life Science Partners LLP, (together "MVM"), have converted £1,000,000 nominal value of the Company's 8% Convertible Unsecured Loan Stock into 4,761,900 ordinary shares of 1 pence each in the Company ("Ordinary Shares").

Following this conversion, MVM holds 24,061,900 Ordinary Shares, representing 9.1% of the Company's issued share capital.

Mr Thomas Casdagli, a non-executive director of the Company, is a partner of MVM Life Sciences Partners LLP and has a beneficial interest in 26,101 Ordinary Shares, representing 0.01% of the Company's issued share capital, and a non-beneficial interest in 24,035,799 Ordinary Shares, representing 9.1% of the Company's issued share capital.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

HOLFSFFWMFDSELE